Results 11 to 20 of about 42,428,678 (264)

beta 2-Glycoprotein I and anti-beta 2-glycoprotein I antibodies: where are we now? [PDF]

Rheumatology, 1997
beta 2-Glycoprotein I (beta 2-GPI), a plasma protein with in vitro anticoagulant properties, has been recognized to have an important role in the antiphospholipid syndrome (APS) as a cofactor and an (co)antigen in ELISA assays. Although beta 2-GPI levels were found to be increased in some patients with APS, the clinical value of measuring beta 2-GPI ...
ISENBERG, DA, Inanc, Murat, RADWAY-BRIGHT, EL   +2 more
openaire   +2 more sources

The Fifth Domain of Beta 2 Glycoprotein I Protects from Natural IgM Mediated Cardiac Ischaemia Reperfusion Injury. [PDF]

PLoS ONE, 2016
Reperfusion after a period of ischemia results in reperfusion injury (IRI) which involves activation of the inflammatory cascade. In cardiac IRI, IgM natural antibodies (NAb) play a prominent role through binding to altered neoepitopes expressed on ...
Peng Zhang, James C Weaver, Gang Chen, Julia Beretov, Tatsuya Atsumi, Miao Qi, Ravinay Bhindi, Jian C Qi, Michele C Madigan, Bill Giannakopoulos, Steven A Krilis   +10 more
doaj   +2 more sources

Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. [PDF]

Lupus, 2021
OBJECTIVE: Anti-beta 2 glycoprotein I IgA is a common isotype of anti-beta 2 glycoprotein I in SLE. Anti-beta 2 glycoprotein I was not included in the American College of Rheumatology (ACR) SLE classification criteria, but was included in the Systemic ...
Elkhalifa M, Orbai AM, Magder LS, Petri M, Alarcón GS, Gordon C, Merrill J, Fortin PR, Bruce IN, Isenberg D, Wallace D, Nived O, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke AE, Aranow C, Manzi S, Urowitz M, Gladman DD, Kalunian K, Werth VP, Zoma A, Bernatsky S, Khamashta M, Jacobsen S, Buyon JP, Dooley MA, Vollenhoven RV, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim S, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG.   +40 more
europepmc   +6 more sources

Anticardiolipin and anti-beta-2-glycoprotein I antibodies

Autoimmunity, 2005
The anticardiolipin (aCL) antibody test was first established in 1983, using cardiolipin (negatively charged phospholipid) as an antigen in a solid-phase immunoassAy. It was first applied to the study of systemic lupus erythematosus patients, and was found associated with thromboses and recurrent pregnancy losses.
Angela Tincani, Genesio Balestrieri
exaly   +4 more sources

Interference of lupus anticoagulant causing antiprothrombin and anti–beta-2-glycoprotein I antibodies on international normalized ratio measurements: comparative analysis of international normalized ratio methods [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Life-long vitamin K antagonist (VKA) therapy is recommended as a standard of care in antiphospholipid syndrome (APS) patients with thrombosis.
Rachel Gehlen, Roxanne G. Moesbergen, CuiCui Bai, Philip G. de Groot, A.J.Gerard Jansen, Joost C.M. Meijers, Bas de Laat, Jasper A. Remijn   +7 more
doaj   +2 more sources

Immune Complexes of Beta-2-Glycoprotein I and IgA Antiphospholipid Antibodies Identify Patients With Elevated Risk of Thrombosis and Early Mortality After Heart Transplantation [PDF]

Frontiers in Immunology, 2019
Background: The presence of anti-Beta 2 glycoprotein antibodies (aB2GP1) of IgA isotype is common in patients with functional impairment of the organs in which B2GP1 is elaborated.
Manuel Serrano, Manuel Serrano, Laura Morán, Jose Angel Martinez-Flores, Esther Mancebo, Daniel Pleguezuelo, Oscar Cabrera-Marante, Juan Delgado, Antonio Serrano, Antonio Serrano   +9 more
doaj   +2 more sources

Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome. [PDF]

Thromb J, 2016
The antiphospholipid syndrome (APS) is an autoimmune disease characterised by a procoagulant state that predisposes to recurrent thrombosis and miscarriages. Two major discoveries have advanced our understanding of the underlying complex pathogenesis of the APS. The first was the discovery that beta-2 glycoprotein-1 (β2GPI) is the major auto antigen in
El-Assaad F, Krilis SA, Giannakopoulos B.   +2 more
europepmc   +5 more sources

Renal Transplantation Dramatically Reduces IgA Anti-beta-2-glycoprotein I Antibodies in Patients with Endstage Renal Disease [PDF]

Journal of Immunology Research, 2014
IgA anti-beta-2-glycoprotein I (aB2GPI) antibodies have been related to vascular pathology in the general population and mainly in hemodialyzed patients (prevalence 33%) in whom an elevated incidence of thrombosis and mortality is found. In this paper we
Manuel Serrano, Jose Angel Martínez-Flores, Maria José Castro, Florencio García, David Lora, Dolores Pérez, Esther Gonzalez, Estela Paz-Artal, Jose M. Morales, Antonio Serrano   +9 more
doaj   +2 more sources

The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation

Haematologica, 2006
BACKGROUND AND OBJECTIVES: Recent evidence suggests that autoantibodies to tissue factor pathway inhibitor (TFPI) and/or antiphospholipid antibodies (aPL) may contribute to upregulation of the tissue factor (TF) pathway of blood coagulation and the ...
SY Lean, P Ellery, L Ivey, J Thom, R Oostryck, M Leahy, R Baker, M Adams   +7 more
doaj   +1 more source

Anticardiolipin and anti‐beta 2‐glycoprotein I antibodies in patients with unexplained articular manifestations [PDF]

Journal of Clinical Laboratory Analysis, 2023
Mankai Amani, Sarra Melayah, Mariam Ghozzi   +2 more
exaly   +2 more sources